Loading
A phase 1 trial of Tozuleristide run by Blaze Bioscience Australia Pty Ltd, completed.
Safety Study of a Fluorescent Marker to Visualize Cancer Cells is a phase 1 interventional study registered as NCT02097875 by Blaze Bioscience Australia Pty Ltd, with 21 participants enrolled, started 2013-12. Conditions recorded: Skin Neoplasms. Interventions recorded: BLZ-100.
Shares Tozuleristide, Blaze Bioscience and the tag pipeline.
Shares Tozuleristide, Blaze Bioscience and the tag pipeline.
Shares Tozuleristide, Blaze Bioscience and the tag pipeline.
Shares Tozuleristide, Blaze Bioscience and the tag pipeline.
Shares Tozuleristide, Blaze Bioscience and the tag pipeline.
Shares Tozuleristide, Blaze Bioscience and the tag pipeline.
Shares Tozuleristide, Blaze Bioscience and the tag pipeline.
Shares Skin cancer (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/